Page last updated: 2024-10-22

albuterol and Bruise

albuterol has been researched along with Bruise in 2 studies

Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.
albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Research Excerpts

ExcerptRelevanceReference
"1465 patients with COPD were recruited from outpatient departments in 25 countries."2.71Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. ( Anderson, J; Calverley, P; Gulsvik, A; Jones, P; Maden, C; Pauwels, R; Pride, N; Vestbo, J, 2003)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calverley, P1
Pauwels, R1
Vestbo, J2
Jones, P1
Pride, N1
Gulsvik, A1
Anderson, J1
Maden, C1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 4 Withdrawal of Inhaled Corticosteroids in Patients With Chronic Obstructive Pulmonary Disease in Primary Care: a Randomised Controlled Trial[NCT00440687]Phase 4256 participants Interventional2001-01-31Completed
GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD)[NCT01787097]Phase 431 participants (Actual)Interventional2013-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes in CXCL8 Levels

Changes in CXCL8 concentrations in sputum compared to screening visit. (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment

Interventionng/mL (Mean)
Formoterol (FORM) Total Dose 24ug-0.04
Symbicort® Total Dose 400ug/12ug-2.1
Symbicort® Total Dose 800ug/24ug-2.2
Pulmicort 800-1.5

Changes in IL-6 Levels

Changes in IL-6 Levels in the sputum supernatant compared to screening visit (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment

Interventionpg/mL (Mean)
Formoterol (FORM) Total Dose 24ug-29
Symbicort® Total Dose 400ug/12ug-14
Symbicort® Total Dose 800ug/24ug-28
Pulmicort 800-29

Changes in Lung Function Parameter FEV1

Improvement in FEV1 compared to baseline levels. (NCT01787097)
Timeframe: Baseline and 2 hours post inhalation

InterventionmL (Mean)
Formoterol (FORM) Total Dose 24ug160
Symbicort® Total Dose 400ug/12ug120
Symbicort® Total Dose 800ug/24ug:200
Pulmicort 800ug52

Changes in TNF Alpha

Sputum TNF-alpha levels obtained from induced sputum compared to screening visit. (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment

Interventionpg/mL (Mean)
Formoterol (FORM) Total Dose 24ug-4.8
Symbicort® Total Dose 400ug/12ug-5.7
Symbicort® Total Dose 800ug/24ug-7.8
Pulmicort 800ug-9.4

GR-GRE Binding (Relative to Baseline)

Enzyme immunosorbent assay system (NCT01787097)
Timeframe: Screening visit and 2 hours post inhalation of treatment

InterventionFold activation (Mean)
Formoterol (FORM) Total Dose 24ug1.1
Symbicort® Total Dose 400ug/12ug1.8
Symbicort® Total Dose 800ug/24ug2.3
Pulmicort 800ug2.1

Trials

2 trials available for albuterol and Bruise

ArticleYear
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou

2003
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou

2003
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou

2003
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou

2003
[Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease].
    Ugeskrift for laeger, 2004, Jan-19, Volume: 166, Issue:4

    Topics: Adrenergic beta-Agonists; Aged; Albuterol; Androstadienes; Anti-Inflammatory Agents; Contusions; Dou

2004